Fairvalue-Calculator Fairvalue-Calculator
EN DE

Handa Pharmaceuticals, Inc (6620) Fair Value & Analysis

Healthcare · TW · Market cap 11.3B TWD

Price90.90 TWD
Fair Value90.02 TWD
Upside-1.0%
Quality95/100
Evidence: High Range 59.80 TWD – 116.03 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Handa Pharmaceuticals, Inc (6620) currently trades at 90.90 TWD, while our model-based Fair Value estimate is 90.02 TWD — implying the stock looks roughly 1.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; Varenicline tablet and HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Handa Pharmaceuticals, Inc (6620) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 90.02 TWD versus a price of 90.90 TWD — about −1% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6620?
Our 21-model fair value for Handa Pharmaceuticals, Inc is 90.02 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 90.90 TWD.
What is the quality score of 6620?
Handa Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.